Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)  Richard B. Warren, Catherine H. Smith, Zenas Z.N. Yiu, Darren M. Ashcroft, Jonathan N.W.N. Barker, A. David Burden, Mark Lunt, Kathleen McElhone, Anthony D. Ormerod, Caroline M. Owen, Nick J. Reynolds, Christopher E.M. Griffiths  Journal of Investigative Dermatology  Volume 135, Issue 11, Pages 2632-2640 (November 2015) DOI: 10.1038/jid.2015.208 Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 1 Crude drug survival of the first biologic course showing disaggregated biologic data (Kaplan–Meier survival curve). Journal of Investigative Dermatology 2015 135, 2632-2640DOI: (10.1038/jid.2015.208) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions

Figure 2 Adjusted drug survival curves using disaggregated data based on the overall multivariate Cox proportional hazard model in Table 4. Journal of Investigative Dermatology 2015 135, 2632-2640DOI: (10.1038/jid.2015.208) Copyright © 2015 The Society for Investigative Dermatology, Inc Terms and Conditions